What is VYCOR MEDICAL INC's earnings per share (EPS)?

VYCOR MEDICAL INC (VYCO) reported diluted earnings per share of -$0.01 for fiscal year 2025. That is unchanged from the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

VYCOR MEDICAL INC (VYCO) Financials

VYCO

FY2025 annual

Revenue $1.9M +17.2% YoY

Net Income -$72K +32.4% YoY

EPS (Diluted) -$0.01 0.0% YoY

Free Cash Flow -$19K -134.1% YoY

Market Cap $2.2M as of Sep 10, 2026

Price / Sales 1.2x on $1.8M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VYCO SEC filings page.

VYCOR MEDICAL INC (VYCO) reported $1.9M in revenue for fiscal year 2025, up 17.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VYCO FY2025 2026-08-29

Near-break-even operations are not repairing a balance sheet burdened by rising liabilities and persistently negative equity.

Operating income was positive in FY2023 and FY2025, yet net income remained negative in both periods; the business can approach operating break-even without converting that progress into bottom-line profitability. The supplied liquidity measure equated cash, cash equivalents, and investments to 77.5 months of reported FY2025 operating outflow, while the current ratio was 0.1; those measures address different claims on resources and should not be treated as interchangeable.

Revenue climbed 27.6% from FY2023 to FY2025, but gross margin slipped from 90.1% to 83.8%; growth therefore came with weaker gross economics rather than clear operating leverage. SG&A also increased 22.0%, absorbing much of the additional gross profit before operating income.

FY2025 liabilities were 6.0x assets, and the current ratio was 0.1, indicating a balance sheet dominated by obligations rather than owned capital. Negative equity deepened from -$3.3M in FY2023 to -$4.1M in FY2025 even as operating income returned positive, so modest operating improvement has not repaired accumulated balance-sheet deficits.

Financial Health Signals

Financial health score not available

VYCOR MEDICAL INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-60.17

VYCOR MEDICAL INC scores -60.17, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.2M) relative to total liabilities ($4.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

VYCOR MEDICAL INC passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

VYCOR MEDICAL INC reported a net loss of $72K while operations used $13K of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$418K

YoY-15.7%

QoQ-8.8%

5Y CAGR-3.2%

10Y CAGR+1.0%

VYCOR MEDICAL INC generated $418K in revenue in Q2 2026. This represents a decrease of 15.7% from the same quarter a year earlier. Against the prior quarter it is down 8.8%.

EBITDA

$22K

YoY-67.1%

QoQ-63.6%

5Y CAGR-12.0%

VYCOR MEDICAL INC's EBITDA was $22K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 67.1% from the same quarter a year earlier. Against the prior quarter it is down 63.6%.

Net Income

-$22K

YoY-193.3%

QoQ-210.8%

VYCOR MEDICAL INC reported -$22K in net income in Q2 2026. This represents a decrease of 193.3% from the same quarter a year earlier. Against the prior quarter it is down 210.8%.

EPS (Diluted)

$0.00

VYCOR MEDICAL INC earned $0.00 per diluted share (EPS) in Q2 2026.

Cash & Balance Sheet

Cash & Debt

$159K

YoY+59.4%

QoQ-8.5%

5Y CAGR+7.9%

10Y CAGR+6.1%

VYCOR MEDICAL INC held $159K in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

33M

YoY0.0%

QoQ0.0%

5Y CAGR+2.0%

10Y CAGR+11.6%

VYCOR MEDICAL INC had 33M shares outstanding in Q2 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

82.3%

YoY-1.3pp

QoQ+0.5pp

5Y change-9.7pp

10Y change-5.0pp

VYCOR MEDICAL INC's gross margin was 82.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.

Operating Margin

1.6%

YoY-8.7pp

QoQ-8.3pp

5Y change-3.1pp

10Y change+78.5pp

VYCOR MEDICAL INC's operating margin was 1.6% in Q2 2026, reflecting core business profitability. This is down 8.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.3 percentage points.

Net Margin

-5.3%

YoY-10.1pp

QoQ-9.7pp

5Y change-3.4pp

10Y change+75.1pp

VYCOR MEDICAL INC's net profit margin was -5.3% in Q2 2026, showing the share of revenue converted to profit. This is down 10.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 9.7 percentage points.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

None of these metrics is reported for Q2 2026.

VYCO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VYCO quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$1.8M	$1.9M+17.2%	$1.6M+8.8%	$1.5M+19.4%	$1.2M-12.2%	$1.4M+22.0%	$1.1M-18.0%	$1.4M-7.7%	$1.5M+9.0%	$1.4M-4.7%	$1.5M+27.6%	$1.1M-8.9%	$1.3M+14.8%	$1.1M-9.6%	$1.2M+24.1%	$971K
Cost of Revenue	$301K	$302K+81.2%	$167K+15.1%	$145K+3.1%	$141K+4.4%	$135K+1.7%	$132K-1.7%	$135K-20.5%	$170K-25.3%	$227K+23.0%	$185K+12.5%	$164K+5.0%	$156K+1.6%	$154K-14.3%	$180K+1.9%	$176K
Gross Profit	$1.5M	$1.6M+9.7%	$1.4M+8.1%	$1.3M+21.6%	$1.1M-14.0%	$1.3M+24.6%	$1.0M-19.8%	$1.3M-6.1%	$1.3M+15.7%	$1.2M-8.7%	$1.3M+30.1%	$975K-10.9%	$1.1M+16.9%	$936K-8.8%	$1.0M+29.0%	$795K
R&D Expenses	N/A	$10K-35.0%	$15K-32.1%	$23K	N/A	$15K	$0	$0	N/A	$3K-36.4%	$5K-93.4%	$72K+3.5%	$69K+29.3%	$53K-57.6%	$126K+9.0%	$116K
SG&A Expenses	$1.4M	$1.5M+7.4%	$1.4M+13.5%	$1.2M-10.2%	$1.3M-17.5%	$1.6M-4.0%	$1.7M-6.6%	$1.8M-17.6%	$2.2M-0.4%	$2.2M-15.6%	$2.6M+2.5%	$2.5M-25.2%	$3.4M+20.5%	$2.8M-17.6%	$3.4M-31.6%	$5.0M
Operating Income	$48K	$34K+470.7%	-$9K-122.8%	$40K+113.1%	-$307K+29.7%	-$436K+40.1%	-$727K-21.0%	-$601K+54.4%	-$1.3M-0.4%	-$1.3M+17.5%	-$1.6M+20.1%	-$2.0M+27.1%	-$2.7M-19.8%	-$2.3M+18.3%	-$2.8M+39.6%	-$4.6M
EBITDA	N/A	$93K+85.4%	$50K-48.4%	$98K+139.3%	-$248K+32.9%	-$370K+44.9%	-$671K-23.9%	-$542K+53.0%	-$1.2M-11.0%	-$1.0M+22.2%	-$1.3M+18.2%	-$1.6M+31.0%	-$2.4M-22.4%	-$1.9M+21.7%	-$2.5M+44.2%	-$4.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$138K+8.5%	$127K
Net Income	-$60K	-$72K+32.4%	-$107K-53.8%	-$70K+82.8%	-$405K+7.1%	-$436K+47.0%	-$822K-3.3%	-$796K+42.3%	-$1.4M+6.6%	-$1.5M+10.6%	-$1.7M+20.7%	-$2.1M+48.6%	-$4.0M-65.7%	-$2.4M+16.6%	-$2.9M+38.7%	-$4.8M
EPS (Basic)	N/A	-$0.010.0%	-$0.010.0%	-$0.01+50.0%	-$0.02+33.3%	-$0.03	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$0.00	-$0.010.0%	-$0.01	-$0.01	-$0.02	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	33M+1.5%	33M	33M	32M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$418K-15.7%	$459K+5.1%	$417K-8.4%	$514K+31.5%	$496K+22.2%	$436K+29.5%	$455K+47.7%	$391K+26.7%
Cost of Revenue	$74K-9.0%	$83K+7.1%	$82K+40.9%	$62K+68.1%	$81K+130.6%	$78K+110.4%	$58K+37.7%	$37K+13.8%
Gross Profit	$344K-17.1%	$375K+4.6%	$335K-15.6%	$452K+27.6%	$415K+11.9%	$359K+19.5%	$397K+49.3%	$354K+28.2%
R&D Expenses	N/A	N/A	N/A	N/A	$4K+85.6%	$6K	N/A	$6K-11.4%
SG&A Expenses	$323K-6.5%	$315K-10.1%	$357K+0.1%	$405K+10.1%	$345K+2.1%	$351K+19.0%	$357K+13.7%	$368K+31.3%
Operating Income	$7K-86.6%	$46K+457.7%	-$37K-288.8%	$32K+191.3%	$51K+216.1%	-$13K-34.3%	$19K+130.2%	-$35K-37.9%
EBITDA	$22K-67.1%	$60K+2782.7%	-$22K-163.2%	$47K+331.9%	$66K+112.6%	$2K-61.2%	$34K+168.9%	-$20K-82.4%
Net Income	-$22K-193.3%	$20K+152.1%	-$63K-830.5%	$5K+108.3%	$24K+338.0%	-$39K-26.0%	-$7K+92.8%	-$60K-15.2%
EPS (Basic)	$0.00	$0.00+100.0%	$0.00	$0.00+100.0%	$0.00	-$0.010.0%	$0.00	-$0.010.0%
EPS (Diluted)	$0.00	$0.00+100.0%	$0.00	$0.00+100.0%	$0.00	-$0.010.0%	$0.00	-$0.010.0%
Diluted Shares (Avg)	33M-13.7%	33M0.0%	N/A	33M+1.4%	39M+18.5%	33M+2.3%	N/A	33M+0.8%

Not reported in any period shown, so not listed: Interest Expense, Income Tax.

VYCO Balance Sheet

VYCO quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$830K-16.8%	$998K+0.6%	$992K+15.4%	$860K-8.0%	$935K-5.2%	$987K-9.7%	$1.1M+4.6%	$1.0M-28.0%	$1.4M-2.4%	$1.5M-26.6%	$2.0M-47.0%	$3.8M+80.3%	$2.1M-17.4%	$2.6M-28.3%	$3.6M
Current Assets	$563K-9.1%	$620K+6.1%	$584K+12.8%	$518K+6.2%	$487K+5.1%	$464K-29.3%	$656K+4.3%	$630K+3.5%	$609K+13.3%	$537K-37.5%	$859K-66.6%	$2.6M+289.9%	$659K-28.7%	$924K-60.3%	$2.3M
Cash & Equivalents	$87K-17.7%	$106K+84.4%	$57K+54.7%	$37K-59.3%	$91K+97.7%	$46K-24.2%	$61K-29.8%	$86K-58.1%	$206K+262.7%	$57K-83.6%	$347K-81.6%	$1.9M+5943.1%	$31K-47.7%	$60K-93.7%	$951K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$159K+9.0%	$146K-37.6%	$234K-5.9%	$249K+19.9%	$208K+14.6%	$181K-13.1%	$208K+2.6%	$203K-5.0%	$214K+4.8%	$204K-30.2%	$293K-12.9%	$336K+62.4%	$207K-28.8%	$291K+57.8%	$184K
Accounts Receivable	$219K-10.8%	$245K+14.0%	$215K+37.8%	$156K+23.9%	$126K-20.8%	$159K-42.0%	$275K+6.6%	$257K+133.2%	$110K-25.8%	$149K+39.9%	$106K-14.1%	$124K-41.8%	$213K+47.3%	$144K-54.0%	$314K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$74K
Total Liabilities	$4.9M+4.9%	$4.7M+8.6%	$4.3M+13.6%	$3.8M+360.4%	-$1.5M-149.2%	$3.0M+21.3%	$2.4M+35.0%	$1.8M+32.5%	$1.4M-9.5%	$1.5M+72.4%	$877K-5.2%	$925K-83.0%	$5.4M+35.1%	$4.0M+49.0%	$2.7M
Current Liabilities	$4.8M+6.3%	$4.5M+10.4%	$4.1M+11.5%	$3.7M+16.0%	$3.1M+14.9%	$2.7M+12.0%	$2.4M+35.0%	$1.8M+32.5%	$1.4M-9.5%	$1.5M+72.4%	$877K-5.2%	$925K-83.0%	$5.4M+35.1%	$4.0M+49.0%	$2.7M
Non-Current Liabilities	$136K-29.1%	$192K-21.2%	$243K+66.3%	$146K-19.0%	$181K-20.5%	$227K	$0	$0	$0	$0	$0	$0-100.0%	$1	$0	$0
Long-Term Debt	N/A	N/A	N/A	N/A	$150K0.0%	$150K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$4.1M-10.8%	-$3.7M-11.0%	-$3.3M-13.1%	-$2.9M-222.8%	$2.4M+220.9%	-$2.0M-46.3%	-$1.4M-76.2%	-$769K-1044.0%	$81K+408.0%	-$26K-102.3%	$1.1M-60.3%	$2.9M+187.1%	-$3.3M-127.4%	-$1.5M-266.5%	$875K
Retained Earnings	-$33.6M-1.2%	-$33.3M-1.3%	-$32.8M-1.2%	-$32.4M-2.3%	-$31.7M-2.5%	-$30.9M-3.8%	-$29.8M-3.9%	-$28.7M-6.3%	-$27.0M-7.2%	-$25.2M-7.9%	-$23.3M-10.7%	-$21.1M-23.8%	-$17.0M-16.8%	-$14.6M-25.1%	-$11.7M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$813K-7.5%	$854K-9.2%	$830K-16.8%	$941K-12.4%	$879K-11.8%	$941K-2.9%	$998K+0.6%	$1.1M+1.9%
Current Assets	$636K+14.7%	$651K+8.4%	$563K-9.1%	$663K-10.9%	$554K-13.9%	$601K+2.1%	$620K+6.1%	$743K+18.8%
Cash & Equivalents	$159K+59.4%	$174K+184.4%	$87K-17.7%	$64K-59.3%	$100K-16.4%	$61K+39.2%	$106K+84.4%	$158K+128.3%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$191K+22.1%	$182K+3.1%	$159K+9.0%	$167K-10.8%	$156K-28.5%	$176K-20.5%	$146K-37.6%	$188K-8.4%
Accounts Receivable	$202K-0.1%	$194K-15.4%	$219K-10.8%	$326K+36.6%	$203K-19.8%	$229K-6.0%	$245K+14.0%	$239K-6.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$5.1M+6.7%	$5.1M+5.2%	$4.9M+4.9%	$5.0M+4.4%	$4.7M+4.9%	$4.8M+7.7%	$4.7M+8.6%	$4.8M+11.0%
Current Liabilities	$4.9M+7.6%	$4.9M+6.3%	$4.8M+6.3%	$4.8M+5.8%	$4.6M+6.4%	$4.7M+9.3%	$4.5M+10.4%	$4.6M+12.9%
Non-Current Liabilities	$134K-18.5%	$135K-24.2%	$136K-29.1%	$150K-26.7%	$164K-24.6%	$178K-22.8%	$192K-21.2%	$205K-19.8%
Total Equity	-$4.3M-9.9%	-$4.2M-8.7%	-$4.1M-10.8%	-$4.0M-9.3%	-$3.9M-9.6%	-$3.9M-10.6%	-$3.7M-11.0%	-$3.7M-14.0%
Retained Earnings	-$33.8M-1.1%	-$33.8M-1.0%	-$33.6M-1.2%	-$33.6M-1.0%	-$33.4M-1.2%	-$33.5M-1.3%	-$33.3M-1.3%	-$33.2M-1.6%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

VYCO Cash Flow Statement

VYCO quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$61K	-$13K-122.4%	$60K+104.2%	$29K+113.6%	-$217K-1115.6%	$21K+108.6%	-$249K-4032.7%	-$6K+97.7%	-$260K+50.6%	-$527K-6.1%	-$497K+57.4%	-$1.2M+56.8%	-$2.7M-256.1%	-$758K+44.7%	-$1.4M+57.1%	-$3.2M
Depreciation & Amortization	N/A	$60K0.0%	$60K+3.5%	$57K-1.3%	$58K-11.9%	$66K+16.9%	$57K-5.6%	$60K-64.0%	$166K-39.6%	$275K+6.9%	$258K-28.5%	$360K-2.2%	$369K+5.2%	$351K+6.6%	$329K+56.6%	$210K
Stock-Based Compensation	N/A	$49K+82.3%	$27K+164.1%	$10K-94.5%	$186K-45.6%	$341K-34.4%	$520K-2.8%	$535K-14.5%	$626K+86.8%	$335K-30.5%	$482K+75.6%	$275K-27.1%	$377K-16.4%	$450K+51.7%	$297K-83.1%	$1.8M
Capital Expenditures	N/A	$5K-2.6%	$5K-42.8%	$9K+237.6%	$3K-92.8%	$38K-38.2%	$62K+17.3%	$53K-16.7%	$64K-65.3%	$183K+219.0%	$57K-72.6%	$210K+60.5%	$131K+2.2%	$128K+354.5%	$28K-54.5%	$62K
Free Cash Flow	N/A	-$19K-134.1%	$55K+173.1%	$20K+109.1%	-$220K-1192.5%	-$17K+94.5%	-$311K-427.5%	-$59K+81.8%	-$324K+54.4%	-$711K-28.2%	-$554K+59.8%	-$1.4M+51.4%	-$2.8M-219.4%	-$886K+36.6%	-$1.4M+57.0%	-$3.3M
Investing Cash Flow	$876	-$4K-4.4%	-$4K+55.3%	-$9K-237.6%	-$3K+92.8%	-$38K+26.9%	-$52K-4.0%	-$50K+20.6%	-$64K+65.3%	-$183K-219.0%	-$57K+80.5%	-$294K-72.0%	-$171K+52.2%	-$358K	N/A	N/A
Financing Cash Flow	-$3K	-$812+89.3%	-$8K-3680.1%	$211-99.9%	$166K+167.8%	$62K-78.4%	$287K+614.8%	$40K-80.0%	$200K-76.8%	$864K+223.9%	$267K+412.7%	-$85K-101.8%	$4.7M+333.9%	$1.1M	N/A	N/A
Dividends Paid	N/A	N/A	N/A	$324K0.0%	$324K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$5K-110.4%	$99K+469.5%	$39K+202.5%	-$72K-791.8%	$47K-45.8%	-$27K-1526.0%	-$38K-795.0%	$10K+170.4%
Depreciation & Amortization	$15K0.0%	$14K-6.0%	$15K0.0%	$15K0.0%	$15K0.0%	$15K0.0%	$15K+3.5%	$15K+3.5%
Stock-Based Compensation	N/A	N/A	N/A	N/A	$0	$18K+674.7%	N/A	$0-100.0%
Capital Expenditures	N/A	N/A	$2K+80150.0%	$1	N/A	N/A	-$2-100.0%	N/A
Free Cash Flow	N/A	N/A	$38K+198.3%	-$72K	N/A	N/A	-$38K-9567.4%	N/A
Investing Cash Flow	$342	$2K	-$2K-1044.7%	$0+100.0%	N/A	N/A	$170+102.9%	-$5K-25.0%
Financing Cash Flow	-$10K-96.8%	-$15K+15.7%	-$15K-7.2%	$37K+12.3%	-$5K+50.9%	-$18K-10.7%	-$14K-22.1%	$33K-4.7%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

VYCO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VYCO quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	83.8%-5.7pp	89.5%-0.6pp	90.1%+1.6pp	88.5%-1.8pp	90.3%+1.9pp	88.4%-1.9pp	90.3%+1.6pp	88.8%+5.2pp	83.6%-3.7pp	87.3%+1.7pp	85.6%-1.9pp	87.5%+1.6pp	85.9%+0.8pp	85.1%+3.2pp	81.8%
Operating Margin	1.8%+2.4pp	-0.6%-3.3pp	2.8%+27.8pp	-25.1%+6.2pp	-31.3%+32.4pp	-63.7%-20.5pp	-43.2%+44.1pp	-87.3%+7.5pp	-94.8%	-109.5%	-174.9%	-218.5%	-209.4%	-231.8%	-476.4%
Net Margin	-3.9%+2.9pp	-6.8%-2.0pp	-4.8%+28.3pp	-33.1%-1.8pp	-31.3%+40.7pp	-72.0%-14.9pp	-57.2%+34.2pp	-91.4%	-106.7%	-113.7%	-182.9%	-323.9%	-224.4%	-243.2%	-491.9%
Return on Equity	N/A	N/A	N/A	N/A	-18.2%	N/A	N/A	N/A	-1813.6%	N/A	-181.8%-41.6pp	-140.2%	N/A	N/A	-545.9%
Return on Assets	-8.7%+2.0pp	-10.7%-3.7pp	-7.0%+40.1pp	-47.1%-0.5pp	-46.6%+36.8pp	-83.4%-10.5pp	-72.9%+59.2pp	-132.1%-30.3pp	-101.9%+9.4pp	-111.3%-8.3pp	-103.0%+3.2pp	-106.2%+9.4pp	-115.6%-1.1pp	-114.5%+19.3pp	-133.8%
Current Ratio	0.120.0x	0.140.0x	0.140.0x	0.140.0x	0.150.0x	0.17-0.1x	0.27-0.1x	0.35-0.1x	0.44+0.1x	0.36-0.6x	0.98-1.8x	2.78+2.7x	0.12-0.1x	0.23-0.6x	0.86
Debt-to-Equity	N/A	N/A	N/A	N/A	0.06	N/A	N/A	N/A	16.80	N/A	0.77+0.4x	0.32	N/A	N/A	3.08
Asset Turnover	2.24+0.7x	1.59+0.1x	1.47+0.1x	1.42-0.1x	1.49+0.3x	1.16-0.1x	1.28-0.2x	1.45+0.5x	0.960.0x	0.98+0.4x	0.56+0.2x	0.33-0.2x	0.520.0x	0.47+0.2x	0.27
FCF Margin	-1.0%-4.4pp	3.4%+2.1pp	1.4%+19.3pp	-18.0%-16.8pp	-1.2%+26.0pp	-27.2%-23.0pp	-4.2%+17.2pp	-21.5%+29.8pp	-51.3%-13.2pp	-38.2%	-121.0%	-226.5%	-81.4%	-116.1%	-335.3%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	82.3%-1.3pp	81.8%-0.3pp	80.5%-6.8pp	88.0%-2.6pp	83.7%-7.7pp	82.2%-6.9pp	87.3%+0.9pp	90.6%+1.1pp
Operating Margin	1.6%-8.7pp	10.0%+12.9pp	-8.8%-13.0pp	6.2%+15.2pp	10.3%+6.3pp	-2.9%-0.1pp	4.3%+25.0pp	-9.0%-0.7pp
Net Margin	-5.3%-10.1pp	4.4%+13.2pp	-15.0%-13.6pp	1.0%+16.3pp	4.8%+7.3pp	-8.8%+0.2pp	-1.5%+28.7pp	-15.3%+1.5pp
Return on Assets	-2.7%-5.5pp	2.4%+6.5pp	-7.5%-6.9pp	0.5%+6.1pp	2.7%+3.7pp	-4.1%-0.9pp	-0.7%+8.7pp	-5.6%-0.6pp
Current Ratio	0.130.0x	0.130.0x	0.120.0x	0.140.0x	0.120.0x	0.130.0x	0.140.0x	0.160.0x
Asset Turnover	0.51-0.1x	0.54+0.1x	0.500.0x	0.55+0.2x	0.56+0.2x	0.46+0.1x	0.46+0.1x	0.36+0.1x
FCF Margin	N/A	N/A	9.0%+17.4pp	-14.1%	N/A	N/A	-8.4%-8.3pp	N/A

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.

Note: Shareholder equity is negative (-$4.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.12), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Where VYCOR MEDICAL INC Ranks

Frequently Asked Questions

What is VYCOR MEDICAL INC's annual revenue?

VYCOR MEDICAL INC (VYCO) reported $1.9M in total revenue for fiscal year 2025. This represents a 17.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is VYCOR MEDICAL INC's revenue growing?

VYCOR MEDICAL INC (VYCO) revenue grew by 17.2% year-over-year, from $1.6M to $1.9M in fiscal year 2025.

Is VYCOR MEDICAL INC profitable?

No, VYCOR MEDICAL INC (VYCO) reported a net income of -$72K in fiscal year 2025, with a net profit margin of -3.9%.

What is VYCOR MEDICAL INC's EBITDA?

VYCOR MEDICAL INC (VYCO) had EBITDA of $93K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is VYCOR MEDICAL INC's gross margin?

VYCOR MEDICAL INC (VYCO) had a gross margin of 83.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is VYCOR MEDICAL INC's operating margin?

VYCOR MEDICAL INC (VYCO) had an operating margin of 1.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is VYCOR MEDICAL INC's net profit margin?

VYCOR MEDICAL INC (VYCO) had a net profit margin of -3.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is VYCOR MEDICAL INC's free cash flow?

VYCOR MEDICAL INC (VYCO) recorded an outflow of $19K in free cash flow during fiscal year 2025. This represents a -134.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is VYCOR MEDICAL INC's operating cash flow?

VYCOR MEDICAL INC (VYCO) recorded an outflow of $13K in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are VYCOR MEDICAL INC's total assets?

VYCOR MEDICAL INC (VYCO) had $830K in total assets as of fiscal year 2025, including both current and long-term assets.

What are VYCOR MEDICAL INC's capital expenditures?

VYCOR MEDICAL INC (VYCO) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does VYCOR MEDICAL INC spend on research and development?

VYCOR MEDICAL INC (VYCO) invested $10K in research and development during fiscal year 2025.

How many shares does VYCOR MEDICAL INC have outstanding?

VYCOR MEDICAL INC (VYCO) had 33M shares outstanding as of fiscal year 2025.

What is VYCOR MEDICAL INC's current ratio?

VYCOR MEDICAL INC (VYCO) had a current ratio of 0.12 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is VYCOR MEDICAL INC's return on assets (ROA)?

VYCOR MEDICAL INC (VYCO) had a return on assets of -8.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is VYCOR MEDICAL INC's P/E ratio?

VYCOR MEDICAL INC (VYCO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $2.2M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is VYCOR MEDICAL INC's price-to-sales ratio?

VYCOR MEDICAL INC (VYCO) trades at 1.2x sales, its market capitalization divided by revenue of $1.8M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.2M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does VYCOR MEDICAL INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, VYCOR MEDICAL INC (VYCO) held $87K in cash, cash equivalents and investments, and reported an operating cash outflow of $13K over that year. Dividing the one by the other, the reported balance equals about 77 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is VYCOR MEDICAL INC's debt-to-equity ratio negative or not reported?

VYCOR MEDICAL INC (VYCO) has negative shareholder equity of -$4.1M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is VYCOR MEDICAL INC's Altman Z-Score?

VYCOR MEDICAL INC (VYCO) has an Altman Z-Score of -60.17, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is VYCOR MEDICAL INC's Piotroski F-Score?

VYCOR MEDICAL INC (VYCO) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are VYCOR MEDICAL INC's earnings high quality?

VYCOR MEDICAL INC (VYCO) reported a net loss of $72K while operations used $13K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.